National Institute of Diabetes and Digestive and Kidney Diseases Notice of Meetings, 38718-38719 [2018-16790]

Download as PDF 38718 Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices daltland on DSKBBV9HB2PROD with NOTICES computational workflows to facilitate chemical safety assessment, by NICEATM. Availability of Report: The report is available at https://ntp.niehs.nih.gov/ iccvamreport/2017/. Links to this report and all past ICCVAM annual and biennial reports are available at https://ntp.niehs.nih.gov/go/iccvam-bien. Background Information on ICCVAM and NICEATM: ICCVAM is an interagency committee composed of representatives from 16 federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. ICCVAM conducts technical evaluations of new, revised, and alternative safety testing methods and integrated testing strategies with regulatory applicability. ICCVAM also promotes the scientific validation and regulatory acceptance of testing methods that more accurately assess the safety and hazards of chemicals and products and replace, reduce, or refine (enhance animal well-being and lessen or avoid pain and distress) animal use. The ICCVAM Authorization Act of 2000 (42 U.S.C. 285l–3) establishes ICCVAM as a permanent interagency committee of NIEHS and provides the authority for ICCVAM involvement in activities relevant to the development of alternative test methods. Additional information about ICCVAM can be found at https://ntp.niehs.nih.gov/go/ iccvam. NICEATM administers ICCVAM, provides scientific and operational support for ICCVAM-related activities, and conducts and publishes analyses and evaluations of data from new, revised, and alternative testing approaches. NICEATM and ICCVAM work collaboratively to evaluate new and improved testing approaches applicable to the needs of U.S. federal agencies. NICEATM and ICCVAM welcome the public nomination of new, revised, and alternative testing approaches for validation studies and technical evaluations. Additional information about NICEATM can be found at https://ntp.niehs.nih.gov/go/ niceatm. Dated: July 24, 2018. Brian R. Berridge, Associate Director, National Toxicology Program. [FR Doc. 2018–16837 Filed 8–6–18; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 16:54 Aug 06, 2018 Jkt 244001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of meetings of the National Diabetes and Digestive and Kidney Diseases Advisory Council. The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council. Date: September 7, 2018. Open: 8:30 a.m. to 12:00 p.m. Agenda: To present the Director’s Report and other scientific presentations. Place: National Institutes of Health, Building 31, C Wing, 6th Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892. Closed: 1:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, C Wing, 6th Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892. Contact Person: Karl F. Malik, Ph.D., Acting Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 5452, Bethesda, MD 20892, (301) 594–4757, malikk@niddk.nih.gov. Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council; Kidney, Urologic and Hematologic Diseases Subcommittee. Date: September 7, 2018. Open: 1:00 p.m. to 2:45 p.m. Agenda: To review the Division’s scientific and planning activities. Place: National Institutes of Health, Building 31, C Wing, 6th Floor, Conference PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 Room 7, 31 Center Drive, Bethesda, MD 20892. Closed: 2:45 p.m. to 3:15 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, C Wing, 6th Floor, Conference Room 7, 31 Center Drive, Bethesda, MD 20892. Contact Person: Karl F. Malik, Ph.D., Acting Director, Division Of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 5452, Bethesda, MD 20892, (301) 594–4757, malikk@niddk.nih.gov. Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council; Diabetes, Endocrinology, and Metabolic Diseases Subcommittee. Date: September 7, 2018. Open: 1:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, C Wing, 6th Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892. Closed: 2:00 p.m. to 3:15 p.m. Agenda: To review the Division’s scientific and planning activities. Place: National Institutes of Health, Building 31, C Wing, 6th Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892. Contact Person: Karl F. Malik, Ph.D., Acting Director, Division Of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 5452, Bethesda, MD 20892, (301) 594–4757, malikk@niddk.nih.gov. Name of Committee: National Diabetes and Digestive and Kidney Diseases Advisory Council; Digestive Diseases and Nutrition Subcommittee. Date: September 7, 2018. Open: 1:00 p.m. to 2:00 p.m. Agenda: To review the Division’s scientific and planning activities. Place: National Institutes of Health, Building 31, C Wing, 6th Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20892. Closed: 2:15 p.m. to 3:15 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, C Wing, 6th Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20892. Contact Person: Karl F. Malik, Ph.D., Acting Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 5452, Bethesda, MD 20892, (301) 594–4757, malikk@niddk.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. E:\FR\FM\07AUN1.SGM 07AUN1 Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: www.niddk.nih.gov/fund/divisions/DEA/ Council/coundesc.htm., where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: August 1, 2018. David D. Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–16790 Filed 8–6–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2018–0495] Merchant Mariner Medical Advisory Committee U.S. Coast Guard, Department of Homeland Security. ACTION: Notice of Federal Advisory Committee Meeting. AGENCY: The Merchant Mariner Medical Advisory Committee and its Working Groups will meet to discuss matters relating to medical certification determinations for issuance of licenses, certificates of registry, and merchant mariners’ documents, medical standards and guidelines for the physical qualifications of operators of commercial vessels, medical examiner education, and medical research. The meetings will be open to the public. DATES: Meetings: The Merchant Mariner Medical Advisory Committee and its Working Groups are scheduled to meet on Thursday, September 13, 2018, and on Friday, September 14, 2018, from 8:00 a.m. until 5:30 p.m. each day. These meetings may adjourn early if the Committee has completed its business. Comments and supporting documentation: To ensure your comments are received by Committee members before the meetings, submit daltland on DSKBBV9HB2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:54 Aug 06, 2018 Jkt 244001 your written comments no later than September 5, 2018. ADDRESSES: The meetings will be held at STAR Center, 2 West Dixie Highway, Dania Beach, FL 33004, https:// www.star-center.com/. Pre-registration Information: Preregistration is not required for access to this meeting by the public. All attendees will be required to provide a driver’s license or government-issued identification card in order to gain admittance to the building. For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact the Alternate Designated Federal Officer as soon as possible using the contact information provided in the FOR FURTHER INFORMATION CONTACT section of this notice. Instructions: You are free to submit comments at any time, including orally at the meetings, but if you want Committee members to review your comment before the meetings, please submit your comments no later than September 5, 2018. We are particularly interested in comments on the issues in the ‘‘Agenda’’ section below. You must include ‘‘Department of Homeland Security’’ and the docket number USCG–2018–0495. Written comments may also be submitted using the Federal eRulemaking Portal at https:// www.regulations.gov. If you encounter technical difficulties with comments submission, contact the individual listed in the FOR FURTHER INFORMATION CONTACT section below. Comments received will be posted without alteration at https://www.regulations.gov, including any personal information provided. You may review the Privacy and Security Notice for the Federal Docket Management System at https:// www.regulations.gov/privacyNotice. Docket Search: For access to the docket, to read documents or comments related to this notice, go to https:// www.regulations.gov, type USCG–2018– 0495 in the ‘‘Search’’ box, press Enter, and then click on the item you wish to view. FOR FURTHER INFORMATION CONTACT: Mr. Davis Breyer, Alternate Designated Federal Officer of the Merchant Mariner Medical Advisory Committee, 2703 Martin Luther King Jr. Ave. SE, Stop 7509, Washington, DC 20593–7509, telephone 202–372–1445, fax 202–372– 8382 or davis.j.breyer@uscg.mil. SUPPLEMENTARY INFORMATION: Notice of this meeting is pursuant with the Federal Advisory Committee Act, Title 5 United States Code Appendix. PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 38719 The Merchant Mariner Medical Advisory Committee Meeting is authorized by U.S. Code, Title 46, section 7115. The Committee advises the Secretary of the Department of Homeland Security on matters related to (a) medical certification determinations for issuance of licenses, certificates of registry, and merchant mariners’ documents; (b) medical standards and guidelines for the physical qualifications of operators of commercial vessels; (c) medical examiner education; and (d) medical research. Agenda Day 1 The agenda for the September 13, 2018, meeting is as follows: (1) The full Committee will meet briefly to discuss the Working Groups’ business/task statements, which are listed under paragraph 2 and 3 (a)–(b) below. (2) General Discussion of Mariner Mental Health Issues with presentations by mariner service organizations and industry. (3) Working Groups will separately address the following task statements, which are available at https:// homeport.uscg.mil/missions/ports-andwaterways/safety-advisory-committees/ medmac. (a) Task statement 16–24 Recommendations on Appropriate Diets and Wellness for Mariners While Onboard Merchant Vessels; and (b) Task statement 17–26, Input to Support Regulatory Reform of Coast Guard Regulations-Executive Orders 13771 and 13783. (4) Public comment period. (5) Reports of Working Groups. At the end of the day, the Working Groups will report to the full Committee on what was accomplished in their meetings. The full Committee will not take action on these reports on this date. Any official action taken as a result of these Working Group meetings will be taken on day two of the meeting. (6) Adjournment of meeting. Day 2 The agenda for the September 14, 2018, meeting is as follows: (1) Introduction. (2) Designated Federal Officer announcements. (3) Remarks from U.S. Coast Guard Leadership. (4) Roll call of Committee members and determination of a quorum. (5) Reports from the following Working Groups: (a) Task statement 16–24, requesting recommendations on appropriate diets E:\FR\FM\07AUN1.SGM 07AUN1

Agencies

[Federal Register Volume 83, Number 152 (Tuesday, August 7, 2018)]
[Notices]
[Pages 38718-38719]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16790]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases 
Notice of Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of meetings of the National Diabetes 
and Digestive and Kidney Diseases Advisory Council.
    The meetings will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Diabetes and Digestive and Kidney 
Diseases Advisory Council.
    Date: September 7, 2018.
    Open: 8:30 a.m. to 12:00 p.m.
    Agenda: To present the Director's Report and other scientific 
presentations.
    Place: National Institutes of Health, Building 31, C Wing, 6th 
Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.
    Closed: 1:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Building 31, C Wing, 6th 
Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Karl F. Malik, Ph.D., Acting Director, Division 
of Extramural Activities, National Institutes of Diabetes and 
Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 
5452, Bethesda, MD 20892, (301) 594-4757, [email protected].

    Name of Committee: National Diabetes and Digestive and Kidney 
Diseases Advisory Council; Kidney, Urologic and Hematologic Diseases 
Subcommittee.
    Date: September 7, 2018.
    Open: 1:00 p.m. to 2:45 p.m.
    Agenda: To review the Division's scientific and planning 
activities.
    Place: National Institutes of Health, Building 31, C Wing, 6th 
Floor, Conference Room 7, 31 Center Drive, Bethesda, MD 20892.
    Closed: 2:45 p.m. to 3:15 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Building 31, C Wing, 6th 
Floor, Conference Room 7, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Karl F. Malik, Ph.D., Acting Director, Division 
Of Extramural Activities, National Institutes of Diabetes and 
Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 
5452, Bethesda, MD 20892, (301) 594-4757, [email protected].

    Name of Committee: National Diabetes and Digestive and Kidney 
Diseases Advisory Council; Diabetes, Endocrinology, and Metabolic 
Diseases Subcommittee.
    Date: September 7, 2018.
    Open: 1:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Building 31, C Wing, 6th 
Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.
    Closed: 2:00 p.m. to 3:15 p.m.
    Agenda: To review the Division's scientific and planning 
activities.
    Place: National Institutes of Health, Building 31, C Wing, 6th 
Floor, Conference Room 10, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Karl F. Malik, Ph.D., Acting Director, Division 
Of Extramural Activities, National Institutes of Diabetes and 
Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 
5452, Bethesda, MD 20892, (301) 594-4757, [email protected].

    Name of Committee: National Diabetes and Digestive and Kidney 
Diseases Advisory Council; Digestive Diseases and Nutrition 
Subcommittee.
    Date: September 7, 2018.
    Open: 1:00 p.m. to 2:00 p.m.
    Agenda: To review the Division's scientific and planning 
activities.
    Place: National Institutes of Health, Building 31, C Wing, 6th 
Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.
    Closed: 2:15 p.m. to 3:15 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Building 31, C Wing, 6th 
Floor, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Karl F. Malik, Ph.D., Acting Director, Division 
of Extramural Activities, National Institutes of Diabetes and 
Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 
5452, Bethesda, MD 20892, (301) 594-4757, [email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.

[[Page 38719]]

    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: www.niddk.nih.gov/fund/divisions/DEA/Council/coundesc.htm., 
where an agenda and any additional information for the meeting will 
be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: August 1, 2018.
David D. Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-16790 Filed 8-6-18; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.